This image is a representation. Your design will be featured in the final product.

Warning: The information provided on this page is for general knowledge purposes only and does not replace the official Instructions for Use (IFU), which are supplied with the medical device. This page does not constitute an electronic IFU either.

NESOSPRAY: Acute rhinosinusitis and Rhinopharyngitis


NESOSPRAY  is an innovative nasal spray designed for the treatment of acute rhinitis,  rhinosinusitis and rhinopharyngitis.  This unique formulation includes a blend of ingredients of vegetal origin.

Available in multiple formulations:

  • NESOSPRAY (NS) adults
  • NESOSPRAY HE (NHE) adults
  • NESOSPRAY HE-G (NHG) adults and children aged twelve (12+) years and over
  • NESOSPRAY-E (NSE) children aged three (3+) years and over


Clinical trial

Randomized, double-blind, placebo-controlled trial

Population

This product is intended for adult use

Indication

NESOSPRAY HE is indicated for the treatment of acute rhinosinusitis and rhinopharyngitis in adults.

Patient's benefits

  • Reduction in rhinorrhoea within 6 days.
  • Improvement in nasal congestion within the first 30 minutes.
  • Reduction in headaches from the third day.
  • Reduction in facial pain from the third day.
  • Reduced use of antibiotics.  


Mode of action


  • Protective Barrier:  It forms a thin, protective film over the mucosa, creating a mechanical barrier that shields it from direct contact with external agressors such as pathogens and environmental factors that can prolong or exacerbate rhinosinutis.
  • Mechanical Cleaning: Utilizes osmotic activity to draw out fluids and irritants, cleansing the nasal mucosa, reducing swelling, and alleviating nasal congestion, indirectly addressing inflammation.
  • Cellular Repair: Promotes healing and regeneration of the mucosa for sustained relief.




Clinical Trial


NESOSPRAY HE has proven effective in treating rhinosinusitis symptoms in a randomized, double-blind, placebo-controlled clinical trial (n = 54).

The spray led to a 58% reduction in nasal congestion within 6 days, with effects starting as early as 30 minutes post-application. Rhinorrhea initially increased due to enhanced secretion clearance, but then decreased by 77% at day 14. Patients also reported rapid improvements in headache (−64%), facial pain (−66%), and postnasal drip (−26%) within 3 days. Only 3% of patients in the NESOSPRAY group required rescue antibiotics vs 19% in the placebo group. The treatment was associated with a marked improvement in quality of life, confirming its efficacy and safety for rhinosinusitis relief.




Product Details  

  • Indication: Used in adults for the treatment of acute rhinitis, rhinosinusitis and rhinopharyngitis.
  • Composition: Made from vegetal origin ingredients
  • Presentation: Nasal spray 15ml.
  • Class: MDR Class IIa.
  • Age: 18+.
  • Storage conditions: Below 25°C.
  • Legal manufacturer: VITROBIO (France).
  • Product code: NHE.


Need more information